Cename ON Behalf OF THE Ministry Pharmaceutical Import Profile — Cameroon (DGFT 2022–2026)

Name: Cename ON Behalf OF THE Ministry Pharmaceutical Import Records from India — 2 Products, $1.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cename ON Behalf OF THE Ministry — Pharmaceutical Importer Profile (2026) | 2 Products, $1.0M Trade | TransData Nexus

Cename ON Behalf OF THE Ministry

Pharmaceutical Importer · Cameroon · Antiviral & HIV Medications Focus · $1.0M Total Trade · DGFT Verified

Cename ON Behalf OF THE Ministry is a pharmaceutical importer based in Cameroon with a total trade value of $1.0M across 2 products in 1 therapeutic categories. Based on 20 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cename ON Behalf OF THE Ministry sources from 8 verified Indian suppliers, with Cipla Limited accounting for 25.7% of imports.

Cename ON Behalf OF THE Ministry — Import Portfolio & Supplier Network

Cename ON Behalf OF THE Ministry import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cename ON Behalf OF THE Ministry?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$357.5K	10	25.7%
Macleods Pharmaceuticals Limited	$264.6K	10	19.0%
Emcure Pharmaceuticals Limited

What Formulations Does Cename ON Behalf OF THE Ministry Import?

Formulation	Value	Ships
Pharma productsfinished product	$200.0K	4
Harmless medicines-artesunate 60MG powder for injection 1 vial Box	$150.0K	3
Dolutegravir as sodium lamivudine tenofovir disoproxil fumarate tablets 50 300 300 MG 12 960 Pack size 1x90	$100.0K	2
Anzavir-r(atazanavir 300MG + ritonavir	$50.0K	1
Sure status covid-19 antigen card test	$50.0K	1
Isoniazid 300MG / rifapentine 300MG	$50.0K	1
Dlt dolutegravir, lamivudine and	$50.0K	1
Dolutegravir TAB 50MG Each TAB	$50.0K	1
Lamivudine and tenofovir df tabs	$50.0K	1
Avocomb tabs Each TAB contains	$50.0K	1
Lamivudine 300MG+tenofovir disoproxil fumarate 300 MG+ dolutegravir sodium 50MG	$50.0K	1
Tenofovir disoproxil fumarate 300MG tablets (30's) (93336 packs : 30's bottle)	$50.0K	1
Lamivudine 300MG tenofovir disoproxilfumarate 300MG dolutegravir 50MG tablets Pack size 1	$50.0K	1
Net cont lamivudine 9384 4980kgs tenofovir disoproxil fumarate 9384 4980kgs dolutegravir sodium 1645	$50.0K	2
Dolutegravir as sodium lamivudine tenofovir disoproxil fumarate tablets 50 300 300 MG 12 876 Pack size 1x90	$50.0K	1

Cename ON Behalf OF THE Ministry imports 40 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Dolutegravir	Antiviral & HIV Medications	$550.0K	11	0.0%	9
2	Tenofovir	Antiviral & HIV Medications	$450.0K	9	0.0%	12

Cename ON Behalf OF THE Ministry imports 2 pharmaceutical products across 1 categories into Cameroon totaling $1.0M.

Cename ON Behalf OF THE Ministry — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

CENAME, the National Supply Centre for Essential Drugs and Medical Consumables, is a public establishment in Cameroon dedicated to ensuring the availability and accessibility of essential medicines and medical devices nationwide. Operating under the technical supervision of the Ministry of Public Health and the financial supervision of the Ministry of Finance, CENAME plays a pivotal role in implementing the national pharmaceutical policy.

Established over two decades ago, CENAME's mission encompasses the procurement, storage, and distribution of essential pharmaceuticals and medical consumables to public health facilities, non-profit private structures, and faith-based health organizations across Cameroon. This centralized approach aims to streamline the supply chain, ensuring that quality medicines are accessible to all citizens.

2Distribution Network

CENAME's distribution network is strategically designed to cover the entire Cameroonian territory, ensuring that essential medicines reach even the most remote areas. The central warehouse, located in Yaoundé, serves as the main hub for procurement and storage. From there, products are dispatched to regional centers and local health facilities, facilitating efficient and timely delivery. This extensive network underscores CENAME's commitment to equitable healthcare access across the country.

3Industry Role

In Cameroon's pharmaceutical supply chain, CENAME functions as the primary wholesaler and distributor of essential medicines and medical devices. By centralizing procurement and distribution, CENAME ensures standardized quality and equitable access to pharmaceuticals across public health facilities. This centralized model is crucial for maintaining the integrity and efficiency of the national healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cename ON Behalf OF THE Ministry

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CENAME's sourcing strategy exhibits a high degree of concentration, with a significant portion of imports originating from India. This focused approach suggests a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities and cost-effectiveness. However, the reliance on a limited number of suppliers may pose risks related to supply chain disruptions or geopolitical factors affecting trade relations. The shipment data indicates a stable relationship with these suppliers, as evidenced by multiple shipments over the years, which may mitigate some of these risks.

2Supply Chain Resilience

CENAME's supply chain resilience is closely tied to the stability and reliability of its Indian suppliers. The presence of multiple suppliers, such as CIPLA Limited, Macleods Pharmaceuticals Limited, and Emcure Pharmaceuticals Limited, provides a degree of diversification. However, the overall concentration on a single source country could expose CENAME to risks associated with disruptions in Indian manufacturing or export policies. Ensuring compliance with international quality standards, such as WHO GMP, among these suppliers is essential for maintaining the integrity of the supply chain.

3Strategic Implications

Importing Pharmaceuticals into Cameroon — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Cameroon

1Regulatory Authority & Framework

In Cameroon, the Ministry of Public Health is the primary regulatory authority overseeing the pharmaceutical sector. CENAME operates under the technical supervision of this ministry, ensuring that its activities align with national health policies and regulations. Key legislation governing pharmaceutical imports includes the Decree No. 2013/234 of 18 July 2013, which regulates the importation and distribution of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining approval from the Ministry of Public Health, ensuring that imported medicines meet the country's safety, efficacy, and quality standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Cameroon mandate that all imported medicines possess a valid marketing authorization from the Ministry of Public Health. Additionally, suppliers must provide evidence of Good Manufacturing Practice (GMP) certification, preferably from recognized bodies such as the World Health Organization (WHO) or the European Union (EU). This ensures that imported products adhere to international quality standards. Wholesale distribution authorization is granted to entities that demonstrate compliance with regulatory requirements, including storage conditions, distribution practices, and record-keeping.

Cename ON Behalf OF THE Ministry — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

CENAME's focus on antiviral and HIV medications, particularly Dolutegravir and Tenofovir, aligns with the high prevalence of HIV/AIDS in Cameroon. The substantial import values of these products indicate a strategic emphasis on addressing this critical public health issue. Market demand for these medications is driven by the need for effective antiretroviral therapies to manage and reduce the transmission of HIV within the population.

2Sourcing Profile

CENAME's sourcing strategy for generic drugs involves procuring formulations that are both cost-effective and meet international quality standards. India's pharmaceutical industry, known for its robust manufacturing capabilities and adherence to GMP, fits well into CENAME's procurement framework. The focus on specific formulations, such as Dolutegravir and Tenofovir, reflects a targeted approach to meet the therapeutic needs of the population.

3Market Positioning

CENAME serves the public health sector in Cameroon, supplying essential medicines to government hospitals, clinics, and other healthcare facilities. By centralizing procurement and distribution, CENAME ensures that these institutions have access to necessary pharmaceuticals, thereby supporting the government's efforts in providing equitable healthcare services to the population.

Seller's Guide — How to Become a Supplier to Cename ON Behalf OF THE Ministry

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with CENAME, especially those offering high-quality generic formulations that meet international standards. Gaps in CENAME's current sourcing may include a limited range of formulations or suppliers, presenting an opportunity for diversification. Establishing partnerships with CENAME could enhance supply chain resilience and ensure a steady supply of essential medicines to the Cameroonian market.

2Requirements & Qualifications

Indian exporters seeking to supply CENAME must obtain a valid marketing authorization from the Ministry of Public Health in Cameroon. They must also provide evidence of GMP certification from recognized bodies such as WHO or the EU. Compliance with labeling requirements, including French language specifications, and adherence to batch testing and stability standards are essential. Additionally, exporters should be prepared to meet serialization mandates to enhance product traceability.

3How to Approach

Frequently Asked Questions — Cename ON Behalf OF THE Ministry

What products does Cename ON Behalf OF THE Ministry import from India?

Cename ON Behalf OF THE Ministry imports 2 pharmaceutical products across 1 categories. Top imports: Dolutegravir ($550.0K), Tenofovir ($450.0K).

Who supplies pharmaceuticals to Cename ON Behalf OF THE Ministry from India?

Cename ON Behalf OF THE Ministry sources from 8 verified Indian suppliers. The primary supplier is Cipla Limited (25.7% of imports, $357.5K).

What is Cename ON Behalf OF THE Ministry's total pharmaceutical import value?

Cename ON Behalf OF THE Ministry's total pharmaceutical import value from India is $1.0M, based on 20 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cename ON Behalf OF THE Ministry focus on?

Cename ON Behalf OF THE Ministry imports across 1 categories. The largest: Antiviral & HIV Medications (100.0%).

Get Full Cename ON Behalf OF THE Ministry Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.